pargyline has been researched along with Brain Damage, Chronic in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| SHARPLEY, P | 1 |
| MENA, A | 1 |
| SCHIELE, BC | 1 |
| HEISTAD, G | 1 |
| TURNER, WJ | 1 |
| MERLIS, S | 1 |
2 other studies available for pargyline and Brain Damage, Chronic
| Article | Year |
|---|---|
A COMPARISON OF PARGYLINE AND TRANYLCYPROMINE WITH AND WITHOUT THE ADDITION OF TRIFLUOPERAZINE: A DOUBLE-BLIND STUDY.
Topics: Biomedical Research; Brain; Brain Damage, Chronic; Depressive Disorder, Major; Double-Blind Method; | 1964 |
A CLINICAL TRIAL OF PARGYLINE AND DOPA IN PSYCHOTIC SUBJECTS.
Topics: Adolescent; Biomedical Research; Brain; Brain Damage, Chronic; Depression; Depressive Disorder, Majo | 1964 |